Bluejay Diagnostics Net Worth

Bluejay Diagnostics Net Worth Breakdown

  BJDX
The net worth of Bluejay Diagnostics is the difference between its total assets and liabilities. Bluejay Diagnostics' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Bluejay Diagnostics' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Bluejay Diagnostics' net worth can be used as a measure of its financial health and stability which can help investors to decide if Bluejay Diagnostics is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Bluejay Diagnostics stock.

Bluejay Diagnostics Net Worth Analysis

Bluejay Diagnostics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bluejay Diagnostics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bluejay Diagnostics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bluejay Diagnostics' net worth analysis. One common approach is to calculate Bluejay Diagnostics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bluejay Diagnostics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bluejay Diagnostics' net worth. This approach calculates the present value of Bluejay Diagnostics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bluejay Diagnostics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bluejay Diagnostics' net worth. This involves comparing Bluejay Diagnostics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bluejay Diagnostics' net worth relative to its peers.

Enterprise Value

(3.48 Million)

To determine if Bluejay Diagnostics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bluejay Diagnostics' net worth research are outlined below:
Bluejay Diagnostics had very high historical volatility over the last 90 days
Bluejay Diagnostics may become a speculative penny stock
Bluejay Diagnostics has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (7.72 M) with profit before overhead, payroll, taxes, and interest of 48.91 K.
Bluejay Diagnostics currently holds about 15.34 M in cash with (7.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76.
Latest headline from news.google.com: Bluejay Diagnostics Inc. Stock Analysis and Forecast - Exceptional stock performance - jammulinksnews.com
Bluejay Diagnostics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bluejay Diagnostics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bluejay Diagnostics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
18th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
18th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Bluejay Diagnostics' Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Bluejay Diagnostics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bluejay Diagnostics backward and forwards among themselves. Bluejay Diagnostics' institutional investor refers to the entity that pools money to purchase Bluejay Diagnostics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Two Sigma Securities, Llc2024-12-31
0.0
Hrt Financial Llc2024-12-31
0.0
Tower Research Capital Llc2025-03-31
1.7 K
Ubs Group Ag2025-03-31
812
Sbi Securities Co Ltd2025-03-31
20.0
Bank Of America Corp2025-03-31
4.0
Sabby Management Llc2024-12-31
0.0
Citadel Advisors Llc2024-12-31
0.0
Renaissance Technologies Corp2024-12-31
0.0
Jump Financial Llc2024-12-31
0.0
Anson Funds Management Lp2024-12-31
0.0
Note, although Bluejay Diagnostics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Bluejay Diagnostics' market capitalization trends

The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.42 M.

Market Cap

975,733

Project Bluejay Diagnostics' profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(1.16)(1.22)
Return On Capital Employed(1.23)(1.29)
Return On Assets(1.16)(1.22)
Return On Equity(1.35)(1.41)
When accessing Bluejay Diagnostics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bluejay Diagnostics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bluejay Diagnostics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bluejay Diagnostics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bluejay Diagnostics. Check Bluejay Diagnostics' Beneish M Score to see the likelihood of Bluejay Diagnostics' management manipulating its earnings.

Evaluate Bluejay Diagnostics' management efficiency

Bluejay Diagnostics has return on total asset (ROA) of (0.8005) % which means that it has lost $0.8005 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.0056) %, meaning that it created substantial loss on money invested by shareholders. Bluejay Diagnostics' management efficiency ratios could be used to measure how well Bluejay Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.22 in 2025. Return On Capital Employed is likely to drop to -1.29 in 2025. At this time, Bluejay Diagnostics' Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 37 K in 2025, whereas Net Tangible Assets are likely to drop slightly above 6.8 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 31.24  28.82 
Tangible Book Value Per Share 31.24  28.79 
Enterprise Value Over EBITDA 0.48  0.50 
Price Book Value Ratio 0.16  0.16 
Enterprise Value Multiple 0.48  0.50 
Price Fair Value 0.16  0.16 
Enterprise Value-3.7 M-3.5 M
Management at Bluejay Diagnostics focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue
5.6745
Return On Equity
(2.01)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bluejay Diagnostics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bluejay Diagnostics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bluejay Diagnostics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bluejay Diagnostics time-series forecasting models is one of many Bluejay Diagnostics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bluejay Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Bluejay Diagnostics Earnings per Share Projection vs Actual

Bluejay Diagnostics Corporate Management

Kenneth CPAChief OfficerProfile
Mr MDChief AdvisorProfile
Kevin VanceChief OfficerProfile
Jason CookChief OfficerProfile
Mark MDChief AdvisorProfile
Les DeLucaVice OperationsProfile
Eryn GrahamMarketing ManagerProfile

Additional Tools for Bluejay Stock Analysis

When running Bluejay Diagnostics' price analysis, check to measure Bluejay Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bluejay Diagnostics is operating at the current time. Most of Bluejay Diagnostics' value examination focuses on studying past and present price action to predict the probability of Bluejay Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bluejay Diagnostics' price. Additionally, you may evaluate how the addition of Bluejay Diagnostics to your portfolios can decrease your overall portfolio volatility.